English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Wistar Institute’s David B. Weiner, Ph.D., and his laboratory created a new therapeutic design for glioblastoma, the deadliest form of brain cancer. The lab engineered molecules called trispecifics that connect cancer-killing T cells with not just one but two different brain cancer receptors.
Tag: Immunotherapy
Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth
A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to work. The study, published in Cancer Cell, explains how a type of cancer cell death can actually make tumors grow faster by turning off the immune system’s ability to fight the cancer.
Diabetes Drug Appears to Fight Lung Cancer — But Only in Overweight or Obese Patients
A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen the effects of immunotherapy and improve recurrence-free survival in people with lung cancer who are overweight or obese, according to a recently published article in the Journal of the National Cancer Institute.
Drug Combination Prompts Immune Response in Some Resistant Pancreatic Cancers
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
Cleveland Clinic Announces Updated Findings in Preventive Breast Cancer Vaccine Study
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The study team found that the investigational vaccine was generally well tolerated and produced an immune response in most patients. The team described the side effects of the vaccine, showed the highest tolerated dose to date, and presented the immunologic effects of the vaccine. Findings are being presented at the Society for Immunotherapy of Cancer Annual Meeting.
Researchers make glioblastoma cells visible to attacking immune cells
Researchers at WashU Medicine have identified a possible way to make glioblastoma cells vulnerable to different types of immunotherapy. The strategy, which they demonstrated in cells in the lab, forces brain cancer cells to display targets for the immune system to attack. Their study was published in Nature Genetics.
Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study, published in the October 30 online issue of Cell used a cutting-edge spatial genomics technology and preclinical animal models, with tumor specimens from ovarian cancer patients further validating the findings. They found that ovarian cancer cells produce a molecule called Interleukin-4 (IL-4), which is typically associated with asthma and the skin condition eczema, also known as atopic dermatitis. The study went on to find that the cancer cells used IL-4 to create a protective environment that kept away killer immune cells, making the tumors resistant to immunotherapy. A drug, dupilumab, which blocks IL-4’s activity, has been approved by the Food and Drug Administration (FDA) and is already used to treat asthma and eczema. This new study suggests dupi
Lymph Node-Like Structures May Trigger the Demise of Cancer Tumors
A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center.
Cancer Research Institute Appoints New Chief Development and Operations Officers to Drive Growth and Innovation
CRI is proud to announce the appointment of Rachael Brown, Chief Development Officer, and Scott Glenn, Chief Operations Officer.
Are Biologics the Future of Food Allergy Treatment? One Study Weighs Pros and Cons
Publishing in Annals of Allergy, Asthma and Immunology, UNC School of Medicine researchers delve into the perspectives of community and academic providers on the role of biologics and food allergy. This study was led by co-authors Edwin Kim, MD, Division Chief of Pediatric Allergy and Immunology, and Jill Fisher, PhD, professor in the UNC Department of Social Medicine and Center for Bioethics.
RESULTS: Study on Advanced-Stage Hodgkin Lymphoma Published in the New England Journal of Medicine
October 17, 2024 – Groundbreaking results from a clinical trial evaluating a novel treatment for advanced-stage classic Hodgkin lymphoma were published today in the New England Journal of Medicine (NEJM). The study, titled “Nivolumab-AVD in Advanced-Stage Classic Hodgkin Lymphoma,” introduces…
Allison Institute scientific symposium features spatial biology breakthroughs, $5 million gift to support further efforts
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific symposium on Oct. 10. The symposium, with more than 900 attendees, featured two Nobel laureates and a $5 million gift from the David and Eula Wintermann Foundation to advance the work of the Allison Institute.
An AI-powered pipeline for personalized cancer vaccines
Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses artificial intelligence algorithms to use its output to design personalized cancer vaccines for patients.
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Researchers at Children’s Hospital of Philadelphia Reveal New Insights into Non-Inflammatory Causes of Rare Neurological Symptoms in Children, Adolescents and Young Adults Following CAR-T Therapy
Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL).
MD Anderson Research Highlights for October 2, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds.
The Cancer Research Institute and the Kidney Cancer Association Announce a Collaboration to Co-Fund Kidney Cancer Immunotherapy Research
The Cancer Research Institute and the Kidney Cancer Association are collaborating on a new kidney cancer immunotherapy research grant.
New combination treatment brings hope to patients with advanced bladder cancer
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results, which were recently published in JAMA Oncology, show potential to broaden the number of patients with bladder cancer who could benefit from immunotherapy, an approach that harnesses a patient’s own immune system to fight cancer.
MD Anderson Research Highlights for September 19, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights Special Edition: ESMO 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Cancer Research Institute (CRI) Appoints Alicia Zhou, PhD, as Chief Executive Officer to Advance Next Generation of Cancer Immunotherapy Science and Innovation
The Cancer Research Institute (CRI) has appointed Alicia Zhou, PhD, as its new Chief Executive Officer (CEO).
Immunotherapy Before and After Lung Cancer Surgery Reduces Death Risk, Disease Recurrence
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
Global Experts Converge at CICON24 to Unveil Groundbreaking Advances in Cancer Immunotherapy, September 8-11, 2024 at National Harbor, MD
CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.
Novel Study Reveals How Aging Immune System Fuels Cancer Growth, Potentially Opening New Avenues for Prevention
A novel study by researchers at the Icahn School of Medicine at Mount Sinai addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer? The study reveals how an aging immune system spurs tumor growth, offering new insights into cancer prevention and treatment, especially for older adults.
MD Anderson Research Highlights for September 4, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.
Novel immunotherapy improves recovery from spinal cord injury
WashU Medicine researchers have designed, in mice, an approach to minimizing the damage from a spinal cord injury through the use of engineered immune cells. Mice given the treatment had improved recovery from injuries, demonstrating potential for developing the therapy for people.
UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy
UCLA has received a $120 million commitment from Dr. Gary Michelson and his wife, Alya, to kick-start the California Institute for Immunology and Immunotherapy, an innovative public-private partnership aimed at spurring breakthrough discoveries that prevent and cure diseases and catalyze economic growth and innovation in Los Angeles.
Immune cells have a metabolic backup plan for accessing their anti-cancer playbook
Immune cells use two different routes to produce acetyl-CoA, an essential metabolite required to fight infection and cancer, reports a study led by Van Andel Institute scientists.
Small molecules, big impact: advancing immune checkpoint inhibitors for cancer
Recent research highlights an approach in cancer therapy with small molecule drugs targeting immune checkpoints. These innovative drugs overcome the limitations of antibody-based inhibitors, such as poor tissue permeability and high production costs.
Targeting cancer with precision: neoantigen vaccines show promise
In an elegant fusion of science and medicine, neoantigen cancer vaccines are emerging as a formidable strategy in the battle against cancer. These vaccines, a testament to the power of personalized medicine, target cancer’s unique protein signatures, rallying the immune system for a precise and potent attack.
Study: Transplant Possible After Immunotherapy for Advanced Liver Cancer Patients
Liver transplant is considered the best treatment for liver cancer, but only available for patients with early-stage disease. Now a study led by Cedars-Sinai Cancer investigators has concluded that immunotherapy could make liver transplant an option for patients with later-stage cancer as well.
Tip Sheet: BRCA cancer risks for men, a new way to classify brain tumors, funding for bile duct cancer — and cancer care in LGBTQ+ communities
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Meteorin-Like Protein Drains Energy From T Cells, Limiting Immune System’s Power to Fight Cancer
A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer.
Improved chemokine homing enhances CAR T–cell therapy for osteosarcoma
Learn how scientists at St. Jude are leading research to improve CAR T-cell therapy for osteosarcoma by enhancing chemokine homing.
Cancer Research Institute Awards Over $22 Million in Grants to Fuel Immunotherapy Innovations
CRI awarded over $22 million to leading cancer immunotherapy researchers in the 2024 fiscal year, amounting to 64 awards at 42 institutions.
MD Anderson and collaborators to launch project studying T cells on International Space Station
The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion.
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Neurosurgeon-scientist elected to Taiwan’s prestigious Academia Sinica
Dr. Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA(Link is external) (Link opens in new window), has been elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.
Summer Safety: What You Should Know About Melanoma
After a cold and rainy winter, it’s refreshing to plan summertime outdoor activities or a day at the beach soaking up the sun. But it’s important to remember that too much sun exposure can be harmful.
MD Anderson Research Highlights for June 19, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Obesity-cancer connection discovery suggests strategies for improving immunotherapy
The study reported in the journal Nature provides a mechanistic explanation for the “obesity paradox” — that obesity can contribute to cancer progression but also improve response to immunotherapy.
How tumor stiffness alters immune cell behavior to escape destruction
Researchers at Sanford Burnham Prebys, with collaborators, illuminate how the fibrotic tumor microenvironment creates an inhospitable milieu for anti-tumor immunity, not just by creating a physical barrier but through metabolic changes that suppress the anti-tumor function of responding immune cells.
UC San Diego Health First in Region to Provide Novel Therapy for Melanoma
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment
Background: Hepatocellular carcinoma (HCC) continues to have a poor prognosis even in the advent of new immunotherapy regimens. An area of growing interest in HCC is its tumor immune microenvironment. Classifying the immune microenvironment based on available genomics can lead to…
Fresh hope for chronic wounds
The U.S. Food and Drug Administration recently approved two new wound management products that include patented hydrogels invented by University of Delaware researchers. The unique UD hydrogel materials self-assemble to form a 3D matrix compatible with living cells.
Plant virus treatment shows promise in fighting metastatic cancers in mice
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.